Impact ledger
Cigna Group (CI): the developments shaping its investment case
Follow the evidence affecting Cigna Group. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Research Cigna Group · $399/mo
Test assumptions, examine opportunities, and save your research.
Material developments
2026-09-18 · 5 reports
Eli Lilly generates $27.7B in 1H GLP-1 sales as Foundayo gains PBM formulary
Channel: Increased prescription volume and formulary management fees for GLP-1 drugs through its PBM segment (Express Scripts).
Bullish· 1-3m
2026-09-18
Eli Lilly H1 GLP-1 sales reach $27.7B as oral obesity pill Foundayo secures PBMs
Channel: As a major Pharmacy Benefit Manager (PBM) through Express Scripts, Cigna securing coverage for a high-demand drug like Foundayo increases prescription volume and potentially administrative fees.
Bullish· 1-3m
Event impact log
6 events mapped to CI since 2026-09-18. Evidence through 2026-09-18.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-09-18 | Eli Lilly generates $27.7B in 1H GLP-1 sales as Foundayo gains PBM formulary | Increased prescription volume and formulary management fees for GLP-1 drugs through its PBM segment (Express Scripts). | Bullish | 1-3m | 0.60 |
| 2026-09-18 | Eli Lilly GLP-1 Franchise Hits $27.7B in H1 2026 as Foundayo Gains PBM Coverage | As a major PBM (Express Scripts), increased formulary coverage for high-demand drugs like Foundayo drives prescription volume and administrative fees. | Bullish | 3-12m | 0.60 |
| 2026-09-18 | Eli Lilly H1 GLP-1 sales reach $27.7B as oral obesity pill Foundayo secures PBMs | As a major Pharmacy Benefit Manager (PBM) through Express Scripts, Cigna securing coverage for a high-demand drug like Foundayo increases prescription volume and potentially administrative fees. | Bullish | 1-3m | 0.60 |
| 2026-09-18 | Eli Lilly GLP-1 Revenue Hits $27.7B in 1H 2026 as Oral Foundayo Expands | As a major Pharmacy Benefit Manager (PBM) through Express Scripts, broad coverage of a high-demand drug like Foundayo increases prescription volume and PBM revenue streams. | Bullish | 3-12m | 0.60 |
| 2026-09-18 | Eli Lilly posts $27.7B 1H GLP-1 revenue as oral obesity drug Foundayo expands | As a major PBM (Express Scripts), formulary access for new, high-cost drugs like Foundayo impacts drug spend, rebate negotiations, and potential for increased prescription volume. | watch | 1-3m | 0.50 |
| 2026-09-18 | Eli Lilly GLP-1 revenue reaches $27.7B in H1 2026 as oral obesity drug expands coverage | As a major Pharmacy Benefit Manager (PBM) through Express Scripts, Cigna's formulary inclusion of a new, high-demand oral obesity drug (Foundayo) suggests increased prescription volume and potential for higher rebate capture. | Bullish | 1-3m | 0.60 |
Continue this research
Build your Cigna Group investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the CI entity page →